Date of Award


Document Type


Degree Name

Master of Physician Assistant Studies


Physician Assistant Education

First Advisor

Rahnea Sunseri


Currently, 1 in 5 U.S. adults are not aware that they have HTN; thus, a minimum of 20% of patients have BPs that are not at goal.7 With such a large number of patients untreated and uncontrolled, efforts have been made to improve patient attainment of these BP goals. Single-pill fixed-dose combination drugs were made available for this purpose. This option reduces medical costs for patients, increases medication compliance, and provides greater therapeutic results. Looking at trends for fixed-dose combination antihypertensive therapy, a commonly used formulation is a thiazide diuretic combined with an ARB.

Per the European Society of Hypertension-European Society of Cardiology guidelines, agents used in combination therapy are more effective when they have complementary mechanisms of action, such as those that occur between a thiazide and an ARB.9 While a thiazide works in the kidney to inhibit sodium reabsorption and increase sodium and water excretion, an ARB blocks angiotensin II receptor effects on cells. ARBs block the vasoconstriction and aldosterone-secretion effects of angiotensin II, consequently inhibiting reabsorption of sodium and water at the distal tubules of the kidneys.10,11 These two drug classes work in conjunction to ultimately lower BP. While the current guidelines suggest that most patients with uncontrolled BP will require two antihypertensive drugs, the next questions to answer are how much of each drug is needed and what numerical drop in BP is required for an effective combination. The dose-dependent side effects of these drugs should also be considered. In particular, some providers find no benefit in treating patients with the lowest dose of hydrochlorothiazide (HCTZ), a common antihypertensive thiazide currently used in practice, and instead start treatment with a moderate dose of HCTZ. On the contrary, some providers find there is no difference in BP lowering effects when comparing low versus moderate HCTZ dosing. This anecdotal information poses the question of whether BP is lowered more effectively with 25 mg of HCTZ compared to 12.5 mg of HCTZ, when used in dual therapy with an ARB, over a minimum course of 8 weeks.

Diep_Presentation Slides.pptx (943 kB)
Click here to download Presentation Slides

Diep_Presentation Slides.pptx (943 kB)
Click here to download Presentation Slides



To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.